Vinblastine and Interferon-Gamma Combination with and without 13-Cis Retinoic Acid for Patients with Advanced Renal Cell Carcinoma

Oncology ◽  
2002 ◽  
Vol 63 (2) ◽  
pp. 130-138 ◽  
Author(s):  
C. Bacoyiannis ◽  
M.A. Dimopoulos ◽  
H.P. Kalofonos ◽  
C. Nicolaides ◽  
G. Aravantinos ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Interferon Gamma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma

Phase II study of interferon gamma (rIFN-G) and vinblastine(VBL) in patients with advanced renal cell carcinoma (RCC)

1997 ◽  
Vol 33 ◽  
pp. S42
Author(s):  
C. Bacoyiannis ◽  
M.A. Dimopoulos ◽  
C. Nicolaides ◽  
G. Aravantinos ◽  
N. Xiros ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Gamma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Advanced Renal Cell Carcinoma

NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma

2020 ◽  
Vol 38 (5) ◽  
pp. 1383-1389
Author(s):  
Ana M. Molina ◽  
Johannes C. van der Mijn ◽  
Paul Christos ◽  
John Wright ◽  
Charlene Thomas ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Trial ◽  
Advanced Renal Cell Carcinoma

Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma

1996 ◽  
Vol 24 (2) ◽  
pp. 101-106 ◽  
Author(s):  
K. H�barth ◽  
A. Hallas ◽  
G. Steiner ◽  
A. Gomahr ◽  
W. Aulitzky ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Interferon Gamma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Immune Markers

Low Activity of 13-cis-Retinoic Acid Plus Interferon Alpha 2a in Advanced Renal Cell Carcinoma

2002 ◽  
Vol 25 (2) ◽  
pp. 123-125 ◽  
Author(s):  
Alejandro V. Jaremtchuk ◽  
Enrique F. Aman ◽  
Walter Ponce ◽  
Juan José Zarbá ◽  
Alejandro M. Ferro ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Cell Carcinoma ◽  
Interferon Alpha ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Low Activity

Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma

2000 ◽  
Vol 18 (16) ◽  
pp. 2972-2980 ◽  
Author(s):  
Robert J. Motzer ◽  
Barbara A. Murphy ◽  
Jennifer Bacik ◽  
Lawrence H. Schwartz ◽  
David M. Nanus ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Retinoic Acid ◽  
Combination Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Interferon Alfa ◽  
Phase Iii ◽  
Advanced Renal Cell Carcinoma ◽  
Partial Recovery ◽  
Phase Iii Trial

PURPOSE: A randomized phase III trial was conducted to determine whether combination therapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFNα2a) is superior to IFNα2a alone in patients with advanced renal cell carcinoma (RCC). PATIENTS AND METHODS: Two hundred eighty-four patients were randomized to treatment with IFNα2a plus 13-CRA or treatment with IFNα2a alone. IFNα2a was given daily subcutaneously, starting at a dose of 3 million units (MU). The dose was escalated every 7 days from 3 to 9 MU (by increments of 3 MU), unless ≥ grade 2 toxicity occurred, in which case dose escalation was stopped. Patients randomized to combination therapy were given oral 13-CRA 1 mg/kg/d plus IFNα2a. Quality of life (QOL) was assessed. RESULTS: Complete or partial responses were achieved by 12% of patients treated with IFNα2a plus 13-CRA and 6% of patients treated with IFNα2a (P = .14). Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P = .03). Nineteen percent of patients treated with IFNα2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNα2a alone (P = .05). Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P = .26). QOL decreased during the first 8 weeks of treatment, and a partial recovery followed. Lower scores were associated with the combination therapy. CONCLUSION: Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNα2a therapy in patients with advanced RCC. 13-CRA may lengthen response to IFNα2a therapy in patients with IFNα2a-sensitive tumors. Treatment, particularly the combination therapy, was associated with a decrease in QOL.

Phase I/II Study of Recombinant Interferon Gamma in Advanced Renal Cell Carcinoma

1988 ◽  
Vol 139 (2) ◽  
pp. 251-255 ◽  
Author(s):  
Marc B. Garnick ◽  
Steven D. Reich ◽  
Barbara Maxwell ◽  
Sherrie Coval-Goldsmith ◽  
Jerome P. Richie ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Interferon Gamma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Recombinant Interferon
Sign in / Sign up

Export Citation Format

Share Document